Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna Ilumya Precertification Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy N/A

    Ilumya (tildrakizumab-asmn) Precertification Request — Coverage Criteria

    Customize your policy alerts

    Sign up for all Aetna policy alerts

    Know when Aetna releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Precertification and clinical information requirements for Aetna members when requesting Ilumya for plaque psoriasis, including documentation needed for initiation and continuation of therapy.

    Policy Summary
    PayerAetna
    PolicyIlumya (tildrakizumab-asmn) Precertification Request — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the completed Ilumya precertification request form with required clinical information including TB testing, prior therapies, BSA, dose and frequency, and provider signature.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2 pagesform length
    plaque psoriasisprimary indicated condition captured on form
    6 monthsrequired tuberculosis test window queried
    BSA %BSA field requested

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Ilumya (tildrakizumab-asmn)

    Initial Therapy (implied)

    Covered when ALL of the following are met (form requests documentation):

    Initial therapy requirements: Patient has diagnosis of moderate to severe plaque psoriasis; requested drug is prescribed by or in consultation with a dermatologist; TB screening performed within 6 months with results documented; documentation of prior therapies (phototherapy, methotrexate, cyclosporine, acitretin) or clinical reason to avoid these agents if BSA <10%; prior biologic or targeted synthetic drug history provided; dose and loading schedule specified on form.

    Form fields collect each element

    Continuation Therapy (implied)

    Continued coverage when ALL of the following are met:

    Continuation therapy requirements: Maintenance dose and frequency specified; patient has achieved or maintained positive clinical response (reduced BSA and improvement in signs/symptoms) since starting treatment; documentation of current receipt through samples or assistance programs indicated; provider signature and date present.

    Form continuation section requests these data

    Use of Ilumya in combination with another biologic or targeted synthetic agent must be clearly indicated on the precertification form. The form asks specifically whether the requested drug will be used in combination with any other biologic (for example, Humira) or targeted synthetic drug (for example, Olumiant, Otezla, Xeljanz), and requires a yes/no response. Concurrent combination use is queried and would require documentation to support the combined regimen.

    Coding and Clinical Data Fields

    Administration/CPT codesCPT
    Administration code(s) (CPT):Place to list CPT administration codes if applicable as indicated on form
    Diagnosis ICD-10 codesICD-10
    Primary ICD Code:Primary diagnosis ICD-10 code field
    Secondary ICD Code:Secondary diagnosis ICD-10 code field
    Other ICD Code:Other diagnosis ICD-10 code field
    inv-06: TB test recency — within 6 months of initiating therapy
    RequirementTB test performed within 6 months of initiating therapy
    Accepted testsPPD (tuberculin skin test), IGRA (interferon‑release assay), or chest x‑ray
    Form fieldCheckbox asks whether TB test was performed within 6 months of initiating therapy
    inv-07: Body Surface Area (BSA) — percentage (numeric field requested)
    Required dataPercentage of body surface area (BSA) affected (numeric %) — prior to starting requested medication
    Crucial areasIndicator whether crucial body areas (hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected
    Step therapy noteIf BSA <10%, form asks about inadequate response or intolerance to phototherapy or methotrexate, cyclosporine, or acitretin

    Provider Actions and Documentation Requirements

    Prior Authorization

    Precertification required

    Precertification is required for Ilumya; submit the Ilumya Medication Precertification Request form with all required clinical information for start or continuation of therapy.

    Step Therapy

    Prior therapy / inadequate response query

    The form asks whether the patient has had an inadequate response or intolerance to phototherapy or systemic agents (methotrexate, cyclosporine, acitretin), and requires this information when BSA is <10%.

    Documentation Required

    Completion requirements

    Complete and legible completion of all required fields on the precertification form is required, including patient demographics, insurance/contact, prescriber and dispensing provider details, product (Ilumya) dose and frequency, and primary/secondary ICD codes; continuation requests must include maintenance dose and frequency.

    • Patient demographics and contact information (chunk 1).
    • Prescriber information including specialty and identifiers (chunk 3).
    • Product information: Ilumya dose and frequency (chunk 5).
    • Diagnosis ICD codes (chunk 6).
    • Continuation-specific fields: maintenance dose/frequency and clinical response (chunk 10).
    • Signature and date required on acknowledgement (chunk 11).
    Denial Risk

    Incomplete documentation risk

    Failure to provide required clinical documentation—such as TB testing history and results within 6 months, prior biologic use, BSA, or leaving required form fields incomplete—may prevent completion of the precertification review and could delay or deny processing.

    • TB test recency and results must be reported (e.g., PPD, IGRA, chest x-ray) (chunk 7).
    • Required clinical fields (prior biologic/targeted synthetic use, BSA, prior treatments/response) must be completed (chunks 7 and 9).
    • Unsigned or undated forms may prompt requests for additional information or result in incomplete review (chunk 11).

    Background

    Ilumya (tildrakizumab-asmn) is a biologic therapy indicated for moderate to severe plaque psoriasis. The Ilumya precertification request form requires documentation of the indication and clinical severity for both new starts and continuation requests.

    For initiation, the form requests documentation that the patient has plaque psoriasis, the proposed loading dose (weeks 0 and 4), the maintenance dose and dosing frequency, prior therapies (including phototherapy and systemic agents), history of prior biologic or targeted synthetic therapy, and tuberculosis (TB) screening performed within 6 months of initiating therapy with test type and result recorded.

    For continuation requests, the form requests the current maintenance dose and frequency, documentation of clinical response or maintained benefit (for example, reduced body surface area and improvement in signs/symptoms), and confirmation of how the patient is currently receiving therapy (including samples or assistance programs). Provider signature and date are required on the acknowledgement section.

    Definitions and Clinical Test Details

    inv-13: TB testing — PPD, IGRA, chest x-ray; results documented as positive/negative/indeterminate
    Screening modalitiesPPD (tuberculosis skin test), interferon‑release assay (IGRA), chest x‑ray
    Result optionsResults to be documented as positive, negative, or unknown/indeterminate
    If positiveForm requires indication of latent vs active TB and whether treatment for latent TB has been initiated, completed, or not initiated
    inv-14: BSA — Body surface area percentage affected by plaque psoriasis to inform severity and step therapy requirements
    DefinitionBody surface area (BSA) percentage affected by plaque psoriasis to inform severity and step therapy requirements
    Numeric fieldForm requests BSA % (prior to starting medication)
    Use in decision-makingIf BSA <10%, the form queries inadequate response or intolerance to phototherapy or systemic agents to justify therapy
    Policy Summary
    PayerAetna
    PolicyIlumya (tildrakizumab-asmn) Precertification Request — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the completed Ilumya precertification request form with required clinical information including TB testing, prior therapies, BSA, dose and frequency, and provider signature.
    SourceLink
    On This Page
    Coverage Criteria for Ilumya (tildrakizumab-asmn)Coding and Clinical Data FieldsProvider Actions and Documentation RequirementsBackgroundDefinitions and Clinical Test Details